Clinical trial
A Study to Evaluate the Effectiveness and Safety of Slow Release Hydromorphone…
NCT00411164 · Alza Corporation, DE, USA, Industry · Completed
Key facts
| NCT number | NCT00411164 |
|---|---|
| Title | A Study to Evaluate the Effectiveness and Safety of Slow Release Hydromorphone HCL for Treatment of Patients With Osteoarthritis |
| Official title | A Phase 3, Randomized, Double-Blind, Fixed-Dose, Parallel Group Comparison of Controlled-Release Hydromorphone HCI vs Placebo in Subjects With Osteoarthritis |
| Lead sponsor | Alza Corporation, DE, USA, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoarthritis, Hip, Knee |
| Intervention type | Drug |
| Interventions | OROS hydromorphone HCI (slow release) |
| Enrollment | 990 |
| Start date | Nov 1, 2003 |
| Completion | May 1, 2005 |
| First posted | Dec 13, 2006 |
| Last update posted | Jul 8, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: